Naples Prognostic Score as an Independent Predictor of Survival Outcomes for Resected Locally Advanced Non-Small Cell Lung Cancer Patients After Neoadjuvant Treatment

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4(6):548–582.
   PubMedGoogle Scholar
• Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–1474.
   PubMed Web of Science ®Google Scholar
• Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):548.
   Web of Science ®Google Scholar
• David EA, Canter RJ, Chen Y, Cooke DT, Cress RD. Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival. Ann Thorac Surg. 2016;102(4):1101–1109.
   Web of Science ®Google Scholar
• Roy MS, Donington JS. Management of locally advanced non small cell lung cancer from a surgical perspective. Curr Treat Options Oncol. 2007;8(1):1–14.
   Google Scholar
• Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: external Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017;12(7):1109–1121.
   PubMed Web of Science ®Google Scholar
• Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299–3306.
   PubMed Web of Science ®Google Scholar
• Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2018;19(8):39.
   Web of Science ®Google Scholar
• Rossi G, Pezzuto A, Sini C, et al. Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019;142:26–34.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830.
   PubMed Web of Science ®Google Scholar
• Tamayo-Bermejo R, Del Rio-Valencia JC, Mora-Rodriguez B, Munoz-Castillo I. Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. J Oncol Pharm Pract. 2021;10781552211061117.
   Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409–1412.
   PubMed Web of Science ®Google Scholar
• Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25(1):50–51.
   PubMed Web of Science ®Google Scholar
• Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol. 2013;30(3):596.
   Web of Science ®Google Scholar
• Zhang X, Moriwaki T, Kawabata T, et al. Nicaraven Attenuates Postoperative Systemic Inflammatory Responses-Induced Tumor Metastasis. Ann Surg Oncol. 2020;27(4):1068–1074.
   Web of Science ®Google Scholar
• Barbetta A, Nobel TB, Sihag S, et al. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg. 2018;106(3):864–871.
   PubMed Web of Science ®Google Scholar
• Huang Q, Diao P, Li CL, et al. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer. Medicine. 2020;99(4):e18607.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today. 2017;47(7):836–843.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang D, Xu WY, Wang YW, Che GW. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: a Meta-Analysis. Oncol Res Treat. 2019;42(10):523–531.
   PubMed Web of Science ®Google Scholar
• Guo D, Zhang J, Jing W, et al. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncology. 2018;14(25):2643–2650.
   Web of Science ®Google Scholar
• Sanabria A, Carvalho AL, Kowalski LP. Is nutrition support related to a poor prognosis in head and neck cancer patients? Thoughts about the secondary analysis of RTOG trial 90-03. Head Neck. 2007;29(5):518–519.
   Web of Science ®Google Scholar
• Sanchez-Lara K, Turcott JG, Juarez E, et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012;64(4):526–534.
   PubMed Web of Science ®Google Scholar
• Imai H, Kishikawa T, Minemura H, et al. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. Cancer Med. 2021;10(20):6971–6984.
   Web of Science ®Google Scholar
• Li W, Qu Y, Wen F, et al. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases. Biomark Med. 2021;15(13):1071–1084.
   PubMed Web of Science ®Google Scholar
• Ohba T, Takamori S, Toyozawa R, et al. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. J Thorac Dis. 2019;11(9):3757–3768.
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Auricchio A, et al. Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. Dis Colon Rectum. 2017;60(12):1273–1284.
   PubMed Web of Science ®Google Scholar
• Jin J, Wang H, Peng F, et al. Prognostic significance of preoperative Naples prognostic score on short- and long-term outcomes after pancreatoduodenectomy for ampullary carcinoma. Hepatobiliary Surg Nutr. 2021;10(6):825–838.
   Web of Science ®Google Scholar
• Xiong J, Hu H, Kang W, et al. Prognostic Impact of Preoperative Naples Prognostic Score in Gastric Cancer Patients Undergoing Surgery. Front Surg. 2021;8:617744.
   PubMed Web of Science ®Google Scholar
• Feng JF, Zhao JM, Chen S, Chen QX. Naples Prognostic Score: a Novel Prognostic Score in Predicting Cancer-Specific Survival in Patients With Resected Esophageal Squamous Cell Carcinoma. Front Oncol. 2021;11:652537.
   Google Scholar
• Nakagawa N, Yamada S, Sonohara F, et al. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Ann Surg Oncol. 2020;27(3):887–895.
   PubMed Web of Science ®Google Scholar
• Li S, Wang H, Yang Z, et al. Naples Prognostic Score as a novel prognostic prediction tool in video-assisted thoracoscopic surgery for early-stage lung cancer: a propensity score matching study. Surg Endosc. 2021;35(7):3679–3697.
   PubMed Web of Science ®Google Scholar
• Li Q, Cong R, Wang Y, et al. Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: results from a retrospective cohort study. Gynecol Oncol. 2021;160(1):91–98.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: review and meta-analysis. Clin Chim Acta. 2018;486:303–310.
   PubMed Web of Science ®Google Scholar
• Li S, Zhang W, Yang Z, Li Y, Du H, Che G. Systemic Inflammation Score as a Novel Prognostic Indicator for Patients Undergoing Video-Assisted Thoracoscopic Surgery Lobectomy for Non-Small-Cell Lung Cancer. J Invest Surg. 2021;34(4):428–440.
   PubMed Web of Science ®Google Scholar
• Cheng X, Li C, Huang J, Lu P, Luo Q. Three-arm robot-assisted thoracoscopic surgery for locally advanced N2 non-small cell lung cancer. J Thorac Dis. 2018;10(12):7009–7013.
   Web of Science ®Google Scholar
• Iwasaki A, Shirakusa T, Maekawa T, Enatsu S, Maekawa S. Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection. Eur J Cardiothorac Surg. 2005;27(1):14–18.
   Web of Science ®Google Scholar
• Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS(R)) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2019;55(1):91–115.
   PubMed Web of Science ®Google Scholar
• Benker M, Citak N, Neuer T, Opitz I, Inci I. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg. 2022;70(3):248–256.
   Web of Science ®Google Scholar
• Pezzuto A, Trabalza Marinucci B, Ricci A, et al. Predictors of respiratory failure after thoracic surgery: a retrospective cohort study with comparison between lobar and sub-lobar resection. J Int Med Res. 2022;50(6):3000605221094531.
   Web of Science ®Google Scholar
• Sun KX, Zheng RS, Zeng HM, et al. The incidence and mortality of lung cancer in China, 2014. Chinese journal of oncology. 2018;40(11):805–811.
   Google Scholar
• Abrams JM. Competition and compensation: coupled to death in development and cancer. Cell. 2002;110(4):403–406.
   Web of Science ®Google Scholar
• Salehi-Rad R, Li R, Paul MK, Dubinett SM, Liu B. The Biology of Lung Cancer: development of More Effective Methods for Prevention, Diagnosis, and Treatment. Clin Chest Med. 2020;41(1):25–38.
   PubMed Web of Science ®Google Scholar
• Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One. 2014;9(9):e106914.
   PubMed Web of Science ®Google Scholar
• Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21(3):527–534.
   Web of Science ®Google Scholar
• Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 1990;76(4):655–663.
   PubMed Web of Science ®Google Scholar
• Zhou N, Liu L, Li D, Zeng Q, Song X. VCS parameters of neutrophils, monocytes and lymphocytes may indicate local bacterial infection in cancer patients who accepted cytotoxic chemotherapeutics. Eur J Clin Microbiol Infect Dis. 2016;35(1):41–48.
   Web of Science ®Google Scholar
• Abu-Shawer O, Abu-Shawer M, Hirmas N, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19(1):141.
   PubMedGoogle Scholar
• Shaul ME, Eyal O, Guglietta S, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020;34(3):4204–4218.
   Web of Science ®Google Scholar
• Vasiljeva O, Papazoglou A, Kruger A, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66(10):5242–5250.
   PubMed Web of Science ®Google Scholar
• Xu F, Cui WQ, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018;37(1):207.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang L, Chen DB, et al. Validation of Prognosis Value of Cumulative Prognostic Scores Based on Serum High-Density Lipoprotein Cholesterol and Albumin Levels in Patients with Colorectal Cancer. J Cancer. 2019;10(1):35–42.
   PubMed Web of Science ®Google Scholar
• Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer. 2004;48(2):171–173.
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Sakamoto Y, Nakagawa S, et al. CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. Int J Colorectal Dis. 2017;32(1):99–106.
   PubMed Web of Science ®Google Scholar
• Kang R, Li P, Wang T, et al. Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population. Sci Rep. 2016;6:19930.
   Web of Science ®Google Scholar
• Lieto E, Auricchio A, Tirino G, et al. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers. 2021;13(18):548.
   Web of Science ®Google Scholar
• Wu H, Fu M, Xie X, et al. Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection. World J Surg Oncol. 2022;20(1):63.
   Web of Science ®Google Scholar